Abstract:Background. Lung adenocarcinoma (LUAD) has been recognized as one of the commonest aggressive malignant tumors occurring in humans. The transforming acidic coiled-coil-containing protein 3 (TACC3) seems to be a probable prognostic marker and treatment target for non-small-cell lung cancer (NSCLC). Nevertheless, there exist no reports on the association between TACC3 and immunotherapy or other therapeutic interventions in LUAD. Methods. Premised on the data accessed from The Cancer Genome Atlas- (TCGA-) LUAD, we carried out bioinformatics analysis. The TACC3 expression in LUAD was analyzed utilizing the GEPIA. A survival module was constructed to evaluate the effect of TACC3 on the survival of patients with LUAD. Logistic regression was undertaken to examine the relationship between TACC3 expression and clinical factors. Protein-protein interaction analysis was performed in the GeneMANIA database, and enrichment analysis and identification of predicted signaling pathways were performed using Gene Ontology and Kyoto Encyclopedia of Genes. Additionally, the Cox regression was used to assess the clinicopathologic features linked to the overall survival in TCGA patients. Lastly, we investigated the link between TACC3 and tumor-infiltrating immune cells (TIICs) through CIBERSORT and the "Correlation " module of GEPIA. The association between TACC3 gene expression and drug response was analyzed using the CellMiner database to predict drug sensitivity. Results. The outcomes illustrated that TACC3 was upregulated and considerably correlated with dismal prognosis in LUAD patients. Moreover, the multivariate Cox regression analysis depicted TACC3 as an independent prognostic marker in LUAD patients. It was also revealed that the expression of TACC3 was related to clinical stage (P=0.014), age (P=0.002), and T classification (P <= 0.018). Moreover, we discovered that the expression of TACC3 was considerably linked to a wide range of TIICs, especially the T cells and NK cells. Single-cell results found that TACC3 was mainly expressed in the immune cells (especially tprolif cells) and malignant cells. TACC3 gene expression was positively correlated with TMB and MSI, and TACC3 may provide a prediction of the efficacy of immunotherapy. Moreover, the correlation analysis between TACC3 gene expression and immune checkpoint gene expression revealed that TACC3 may coordinate the activities of these ICP genes in different signal transduction pathways. TACC3 is related to biological progress (BP), cellular component (CC), and molecular function (MF). The pathways involved in the interaction network involving TACC3 include nonhomologous end-joining, RNA transport, pantothenate and CoA biosynthesis, homologous recombination, and nucleotide excision repair. Furthermore, we investigated the association between the expression of TACC3 and the use of antitumor drugs, and TACC3 was positively correlated with response to most drugs. Conclusion. The findings from this research offer robust proof that the expression of TACC3 could be a prognostic marker correlated with TIICs in LUAD. TACC3 can also provide new ideas for immunotherapy as a potential therapeutic target.

Expression and Clinical Significance of Activating Transcription Factor 3 in Human Breast Cancer

Identification of ATFs in Human Breast Cancer by Integrated Bioinformatic Analysis

A Bioinformatic Analysis Found Low Expression and Clinical Significance of ATF4 in Breast Cancer

Activating transcription factor 3 is a new biomarker correlation with renal clear cell carcinoma progression

Low Expression of Activating Transcription Factor 3 in Human Hepatocellular Carcinoma and Its Clinicopathological Significance

Association Between the Atf3 Gene and Non-Small Cell Lung Cancer

Overexpression of the Transcription Factor ATF3 with a Regulatory Molecular Signature Associates with the Pathogenic Development of Colorectal Cancer

ATF3 Demethylation Promotes the Transcription of ARL4C, Which Acts As a Tumor Suppressor in Human Breast Cancer

Activating Transcription Factor 3 Promotes Colon Cancer Metastasis

ATF3 Inhibits the Tumorigenesis and Progression of Hepatocellular Carcinoma Cells Via Upregulation of CYR61 Expression

Expression of GATA3 in breast tumor and its clinical significance

Association of GATA3 expression in triple-positive breast cancer with overall survival and immune cell infiltration

Expression of STAT3 gene in breast carcinoma and its clinical significance

The Clinical Significance of Transforming Acidic Coiled-Coil Protein 3 Expression in Non-Small Cell Lung Cancer.

Activating Transcription Factor 2 Expression Mediates Cell Proliferation and is Associated with Poor Prognosis in Human Non-Small Cell Lung Carcinoma.

Upregulation of ZMAT3 is Associated with the Poor Prognosis of Breast Cancer

TOX3 Protein Expression is Correlated with Pathological Characteristics in Breast Cancer.

ATF3 Transcription Factor and Its Emerging Roles in Immunity and Cancer

TACC3 As an Independent Prognostic Marker for Solid Tumors: a Systematic Review and Meta-Analysis.

Expression of Activating Transcription Factor 7 is Correlated with Prognosis of Colorectal Cancer

High Expression of <i>TACC3</i> Is Associated with the Poor Prognosis and Immune Infiltration in Lung Adenocarcinoma Patients